PL DEVELOPMENTS — Docusate Importer Profile
Pharmaceutical Importer · #1 buyer for Docusate · $3.5M import value · 99 shipments · UNITED STATES · DGFT Verified
PL DEVELOPMENTS is the #1 importer of Docusate from India with $3.5M in import value and 99 verified shipments. PL DEVELOPMENTS holds a 53.4% market share in Docusate imports based in UNITED STATES. The company sources from 2 verified suppliers across 33 formulations shipped to 1 country. Overall, PL DEVELOPMENTS imports 7 pharmaceutical products worth $18.3M across 6 therapeutic categories.
PL DEVELOPMENTS — Docusate Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Docusate to PL DEVELOPMENTS?
Verified from 99 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| TRUECARE BIOMEDIX | $3.0M | 88 | 85.5% |
| TRUE CARE BIOMEDIX | $509.3K | 11 | 14.5% |
PL DEVELOPMENTS sources Docusate from 2 verified Indian suppliers based on 99 customs records. The primary supplier is TRUECARE BIOMEDIX accounting for 85.5% of imports.
How Does PL DEVELOPMENTS Compare to Nearest Docusate Importers?
Buyers ranked immediately above and below #1 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | PL DEVELOPMENTS ★ | UNITED STATES | $5.0M | 99 | $50.0K |
| 2 | GERICARE PHARMACEUTICALS CORP. | UNITED STATES | $1.2M | 32 | $36.8K |
| 3 | GENERIC HEALTH | AUSTRALIA | $371.2K | 11 | $33.7K |
PL DEVELOPMENTS ranks #1 among 158 Docusate importers from India. Average shipment value of $50.0K compared to the market average of $53.0K. The closest competitors by value are GERICARE PHARMACEUTICALS CORP. and GENERIC HEALTH.
Where Does PL DEVELOPMENTS Import Docusate To?
Destination countries from 99 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $3.5M | 99 | 100.0% |
PL DEVELOPMENTS imports Docusate to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $3.5M.
What Docusate Formulations Does PL DEVELOPMENTS Import?
| Formulation | Value | Shipments |
|---|---|---|
| Sennosides & Docusate Sodium Tablet 8.6m | $1.1M | 26 |
| SENNOSIDES & DOCUSATE SODIUM TABLET 8.6MG/50MG (RED) OTHER DETAILS AS PER INV &PL.NOS | $213.2K | 6 |
| Sennosides & Docusate Sodium Tablet 8.6mg/50mg (Red) | $213.1K | 5 |
| SENNOSIDES & DOCUSATE SODIUM TABLET 8.6MG/50MG (RED) EACH FILM COATED TABLET CONTAINS:SENNOSIDES USP 8.6MG AS PER INVNOS | $205.0K | 6 |
| SENNOSIDES & DOCUSATE SODIUM TABLET 8.6MG/50MG (RED) OTHER DETAILS AS PER INV &PL. | $159.0K | 5 |
| Sennosides Docusate Sodium Tablet 8 6mg 50mg Red OTHER DETAILS AS PER INV PL | $150.0K | 3 |
| Sennosides & Docusate Sodium Tablet 8.6mg/50mg Red OTHER DETAILS AS PER DOCUMENT &PL. | $150.0K | 3 |
| SENNOSIDES & DOCUSATE SODIUM TABLET 8.6MG/50MG (RED) EACH FILM COATED TABLET CONTAINS:SENNOSIDES USP 8.6MG AS PER INV | $118.6K | 4 |
| Sennosides & Docusate Sodium Tablet 8.6mg/50mg Orange OTHER DETAILS AS PER INV& PL. | $100.0K | 2 |
| SENNOSIDES & DOCUSATE SODIUM Tablet 8.6mg/50mg (Red) | $100.0K | 2 |
PL DEVELOPMENTS imports 33 distinct Docusate formulations from India. The top formulation is Sennosides & Docusate Sodium Tablet 8.6m with 26 shipments worth $1.1M.
Regulatory Requirements: Importing Docusate into United States
What PL DEVELOPMENTS and other importers must comply with to import Docusate from India
Regulatory Authority
U.S. Food and Drug Administration (FDA)
Approval Process for Generic Docusate
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
GMP Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
Import Licence & Documentation
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
Labeling & Packaging
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Docusate from India and How Much Does PL DEVELOPMENTS Import?
India exported $8.4M worth of Docusate through 453 shipments from 25 suppliers to 35 countries, serving 158 buyers globally. PL DEVELOPMENTS imports $3.5M of this total, accounting for 53.4% of India's Docusate exports with 99 shipments from UNITED STATES. This is verified from 99 customs shipment records covering 33 distinct formulations.
What Is the Average Order Value for PL DEVELOPMENTS's Docusate Imports?
PL DEVELOPMENTS's average Docusate order value is $35.4K per consignment, based on 99 shipments totaling $3.5M. PL DEVELOPMENTS is based in UNITED STATES and ranks #1 among all Docusate importers from India by value. The company sources from 2 verified suppliers in India.
Who Supplies Docusate to PL DEVELOPMENTS?
PL DEVELOPMENTS sources Docusate from 2 verified Indian suppliers: TRUECARE BIOMEDIX ($3.0M, 85.5%), TRUE CARE BIOMEDIX ($509.3K, 14.5%). This is based on 99 customs records.
How Does PL DEVELOPMENTS Compare to Other Docusate Importers?
PL DEVELOPMENTS ranks #1 among 158 Docusate importers from India with a 53.4% market share. The top 3 importers are PL DEVELOPMENTS ($5.0M), GERICARE PHARMACEUTICALS CORP. ($1.2M), GENERIC HEALTH ($371.2K). PL DEVELOPMENTS processed 99 shipments from UNITED STATES.
About PL DEVELOPMENTS
PL DEVELOPMENTS imports 7 products worth $18.3M. Beyond Docusate, top products include Nicotine, Miconazole, Diphenhydramine, Clotrimazole, Aspirin. View the complete PL DEVELOPMENTS profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Docusate — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Docusate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: PL DEVELOPMENTS matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as PL DEVELOPMENTS's capped import value divided by total capped export value for Docusate across all Indian exporters.
- 5.Verified Records: This page is backed by 99 individual customs records matching PL DEVELOPMENTS importing Docusate, covering 33 formulations from 2 verified suppliers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 35+ countries, 158+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Docusate Import Data for PL DEVELOPMENTS
Access order-level details, pricing data, supplier connections, and competitive analysis for PL DEVELOPMENTS's Docusate imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
PL DEVELOPMENTS
Full Company Profile →
7 products · $18.3M total trade · 6 categories
PL DEVELOPMENTS × Docusate
Verified from customs records
Company Overview
Top Products by PL DEVELOPMENTS
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for PL DEVELOPMENTS.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Docusate. For current order-level data, contact TransData Nexus.